navirepharma.com | Navire Pharma | Developing SHP2 Inhibitors To Treat

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Allow: /wp-admin/admin-ajax.php Disallow: /wp-admin/ Sitemap: https://navirepharma.com/sitemap.xml Sitemap:

Meta Tags

Title	Navire Pharma \| Developing SHP2 Inhibitors To Treat
Description	Targeting SHP2 for patients with Navire Pharma is developing SHP2 inhibitors as potentially effective additions to the therapeutic arsenal for difficult-to-treat cancers. Learn more
Keywords	N/A

Server Information

WebSite	navirepharma.com
Host IP	162.159.134.42
Location	United States

Related Websites

                        Site
                        Rank
                    

More to Explore

navirepharma.com Valuation

US$4,641,994

Last updated: 2023-05-12 20:31:09

navirepharma.com has Semrush global rank of 2,280,120. navirepharma.com has an estimated worth of US$ 4,641,994, based on its estimated Ads revenue. navirepharma.com receives approximately 535,615 unique visitors each day. Its web server is located in United States, with IP address 162.159.134.42. According to SiteAdvisor, navirepharma.com is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$4,641,994
Daily Ads Revenue	US$4,285
Monthly Ads Revenue	US$128,548
Yearly Ads Revenue	US$1,542,571
Daily Unique Visitors	35,708
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
navirepharma.com.	A	599	IP: 162.159.134.42
navirepharma.com.	NS	3600	NS Record: ns64.domaincontrol.com.
navirepharma.com.	NS	3600	NS Record: ns63.domaincontrol.com.
navirepharma.com.	MX	600	MX Record: 10 navirepharma-com.mail.protection.outlook.com.
navirepharma.com.	TXT	600	TXT Record: ppe-3dbe74411b17ad196097
navirepharma.com.	TXT	600	TXT Record: docusign=eafd645a-33aa-427e-b9ef-852b9ee5abc5
navirepharma.com.	TXT	600	TXT Record: NETORGFT3185618.onmicrosoft.com
navirepharma.com.	TXT	600	TXT Record: MS=ms85571872
navirepharma.com.	TXT	600	TXT Record: v=spf1 include:spf.protection.outlook.com a:dispatch-us.ppe-hosted.com ~all
navirepharma.com.	TXT	600	TXT Record: knowbe4-site-verification=621770f29dd02324b411b937da52b3c3

HtmlToTextCheckTime:2023-05-12 20:31:09

Home Science About Us Leadership Parent Company News Access Policy Contact Menu Menu Targeting SHP2 for patients with cancer . Navire Pharma is developing SHP2 inhibitors as potentially effective additions to the therapeutic arsenal for difficult-to-treat cancers. Learn More Science SHP2 SHP2 (Src homology region 2-containing protein tyrosine phosphatase, encoded by the PTPN11 gene) is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. Overactivity of this pathway — often driven by distinct genetic mutations — is the fundamental cause of, or a critical contributor to, many forms of cancer, and is a mechanism of resistance to several targeted therapies. Inhibiting SHP2 offers a novel approach to potentially treat tumors driven by this pathway. Navire Approach Navire Pharma is developing small molecules to treat cancers driven by increased activity of

HTTP Headers

HTTP/1.1 301 Moved Permanently
Date: Mon, 20 Dec 2021 00:03:15 GMT
Content-Type: text/html
Content-Length: 162
Connection: keep-alive
Location: https://navirepharma.com/
CF-Ray: 6c049b440c315589-EWR
CF-Cache-Status: DYNAMIC
ki-edge: v=16.6
X-Content-Type-Options: nosniff
X-Edge-Location-Klb: 1
Server: cloudflare
alt-svc: h3=":443"; ma=86400, h3-29=":443"; ma=86400, h3-28=":443"; ma=86400, h3-27=":443"; ma=86400

HTTP/2 200 
date: Mon, 20 Dec 2021 00:03:16 GMT
content-type: text/html; charset=UTF-8
cf-ray: 6c049b45eaf6efe9-EWR
link: ; rel="https://api.w.org/", ; rel="alternate"; type="application/json", ; rel=shortlink
vary: Accept-Encoding
cf-cache-status: DYNAMIC
expect-ct: max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
ki-edge: v=16.6
x-content-type-options: nosniff
x-edge-location-klb: 1
x-kinsta-cache: MISS
server: cloudflare
alt-svc: h3=":443"; ma=86400, h3-29=":443"; ma=86400, h3-28=":443"; ma=86400, h3-27=":443"; ma=86400

navirepharma.com Whois Information

Domain Name: NAVIREPHARMA.COM
Registry Domain ID: 2122146539_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2017-05-08T23:39:47Z
Creation Date: 2017-05-08T23:39:47Z
Registry Expiry Date: 2022-05-08T23:39:47Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: abuse@godaddy.com
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS63.DOMAINCONTROL.COM
Name Server: NS64.DOMAINCONTROL.COM
DNSSEC: unsigned
>>> Last update of whois database: 2021-12-23T08:41:08Z <<<

navirepharma.com valuation and analysis